Integrative approaches to elucidate p53 transcriptional networks during carcinogenesis

阐明致癌过程中 p53 转录网络的综合方法

• 批准号: 9319674
• 负责人: LAURA D ATTARDI
• 金额: $ 97.6万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-14 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9319674
• 关键词: Apoptosis; Biochemical; Biological; CRISPR screen; Cell Cycle Progression; Cell Proliferation; Cell physiology; Cells; ChIP-seq; Development; Disease; Ductal Epithelial Cell; Fibroblasts; Gene Targeting; Genes; Genetic; Genetic Transcription; Genomics; Goals; Individual; Knock-in Mouse; Knowledge; Malignant Neoplasms; Malignant neoplasm of pancreas; Mass Spectrum Analysis; Mediating; Mediator of activation protein; Metabolism; Missense Mutation; Mus; Mutate; Mutation; Neoplasm Metastasis; Pancreatic duct; Pathway interactions; Play; Premalignant; Prevention strategy; Property; Protein p53; Research; Role; Small Interfering RNA; Survival Rate; TP53 gene; Therapeutic; Transcriptional Activation Domain; Tumor Suppression; Tumor Suppressor Proteins; Tumor-Derived; Work; carcinogenesis; gain of function; gene function; in vivo Model; insight; knock-down; mutant; novel; overexpression; prevent; programs; protein function; public health relevance; screening; transcription factor; transcriptome sequencing; treatment strategy; tumor; tumorigenesis

 DESCRIPTION (provided by applicant): The p53 transcription factor plays a pivotal role in tumorigenesis. p53 inactivation in tumors, which occurs typically through missense mutation, unequivocally promotes cancer, but the mutated p53 protein also displays gain-of-function (GOF) properties that promote cancer. In this proposal, we strive to deconstruct the transcriptional programs through which wild-type p53 suppresses cancer and through which missense mutant p53 exerts GOF effects to promote cancer. We propose to use integrated genetic, genomic, cell biological and biochemical approaches to define the p53 transcriptional programs critical for p53-mediated suppression of pancreatic cancer, a deadly cancer with a mere 6% 5-year survival rate and which is typically associated with p53 mutation. Our proposed work builds on initial studies of a unique panel of p53 transcriptional activation domain (TAD) mutant knock-in mice that we generated to define the downstream p53 transcriptional targets most essential for suppressing cancer development. A particularly powerful mutant is the TAD1 mutant, known as p5325,26, which is severely compromised for activation of most known p53 target genes yet still efficiently transactivates a small set of novel p53-dependent genes in fibroblasts and still retains full activity in suppressing a variety of cancers. In addition, the TD2 mutant, p5353,54 can hyperactivate a subset of p53 target genes and behaves as a super-tumor suppressor. The p53 "tumor suppression associated target genes" (TSAGs) activated by the p5325,26 and p5353,54 mutants largely represent novel p53 targets, which we hypothesize are critical for tumor suppression and therefore have great potential to expand our current knowledge of p53 tumor suppression mechanisms. Here, we propose to perform ChIP-seq and RNA-seq in premalignant pancreatic ductal epithelial cells expressing these mutants to identify TSAGs associated with pancreatic cancer suppression. We then propose to identify key mediators of p53 function in tumor suppression by performing CRISPR screening in mouse pancreas cancer models in vivo to identify combinations of p53 TSAGs whose loss promotes cancer. We will define the cellular functions of the proteins encoded by p53 TSAGs in different cellular processes regulated by p53, including cell-cycle progression, apoptosis, metabolism, and invasion/metastasis, using overexpression and knockdown approaches. Detailed analyses of p53 TSAG function will help elucidate cellular functions most critical for tumor suppression. We will next use mass spectrometry and siRNA screening to identify the co-factors through which the TADs act to induce p53 TSAGs and to suppress pancreatic cancer, providing another level of understanding of tumor suppression. Finally, we will leverage our expertise in studying p53 TADs to define the importance of TADs for p53 GOF activity. We will use a systematic approach to analyze the TADs at the genetic, genomic and biochemical levels to understand how tumor-derived p53 GOF mutants exert their effects. Collectively, these studies will provide crucial insight into how to modulate p53 pathways during therapeutic strategies for cancer.

 描述（由申请人提供）：p53转录因子在肿瘤发生中起关键作用。肿瘤中的p53失活通常通过错义突变发生，明确地促进癌症，但突变的p53蛋白也显示出促进癌症的功能获得（GOF）特性。在这个提议中，我们努力解构野生型p53抑制癌症和错义突变型p53发挥GOF效应促进癌症的转录程序。我们建议使用综合遗传学，基因组学，细胞生物学和生物化学的方法来定义p53转录程序的p53介导的抑制胰腺癌，一个致命的癌症，只有6%的5年生存率，这是典型的p53突变相关的关键。我们提出的工作建立在一个独特的面板p53转录激活结构域（p53）突变敲入小鼠，我们产生了定义下游p53转录抑制癌症发展最重要的目标的初步研究。一个特别强大的突变体是TAD 1突变体，称为p5325，26，它严重损害了大多数已知的p53靶基因的激活，但仍然有效地反式激活成纤维细胞中的一小部分新的p53依赖性基因，并且仍然保留了抑制各种癌症的全部活性。此外，TD 2突变体p5353，54可以过度激活p53靶基因的一个子集，并表现为超级肿瘤抑制因子。由p5325，26和p5353，54突变体激活的p53“肿瘤抑制相关靶基因”（TSAG）在很大程度上代表了新的p53靶点，我们假设这些靶点对肿瘤抑制至关重要，因此有很大的潜力来扩展我们目前对p53肿瘤抑制机制的认识。在这里，我们建议在表达这些突变体的癌前胰腺导管上皮细胞中进行ChIP-seq和RNA-seq，以鉴定与胰腺癌抑制相关的TSAG。然后，我们提出通过在小鼠胰腺癌模型中进行CRISPR筛选来鉴定p53在肿瘤抑制中的关键介导物，以鉴定其损失促进癌症的p53 TSAG的组合。我们将定义由p53 TSAG编码的蛋白质在不同的细胞过程中的细胞功能，包括细胞周期进程，细胞凋亡，代谢和侵袭/转移，使用过表达和敲低的方法。p53 TSAG功能的详细分析将有助于阐明对肿瘤抑制最关键的细胞功能。接下来，我们将使用质谱和siRNA筛选来鉴定TADs诱导p53 TSAG并抑制胰腺癌的辅助因子，从而提供对肿瘤抑制的另一个层次的理解。最后，我们将利用我们在研究p53 TADs方面的专业知识来定义TADs对p53 GOF活性的重要性。我们将使用系统的方法在遗传、基因组和生化水平上分析TADs，以了解肿瘤来源的p53 GOF突变体如何发挥其作用。总的来说，这些研究将为如何在癌症治疗策略中调节p53通路提供重要的见解。